Nonmyeloablative Stem Cell Transplant in Children With Sickle Cell Disease and a Major ABO-Incompatible Matched Sibling Donor
Condition(s) studied
Investigational drug(s) / intervention(s)
Alemtuzumab: Alemtuzumab, Day -7 to -3. Dose: 0.2mg/kg/dose SC once daily x 5 days
Total Body Irradiation: TBI 300 cGy on Day -2
Sirolimus: Sirolimus is used for GVHD prophylaxis
Study summary
The aim of this study to evaluate the safety and efficacy of a nonmyeloablative conditioning regimen for allogeneic hematopoietic stem cell transplantation (HSCT) in pediatric patients with sickle cell disease (SCD) who have a matched related major ABO-incompatible donor. The nonmyeloablative regimen will use alemtuzumab, total body irradiation (TBI) and sirolimus for immune suppression. This study will expand the access of HSCT for patients with SCD who are currently not eligible because of donor restrictions.
Eligibility
Primary outcome measure(s)
- Incidence of pure red cell aplasia (PRCA) — 6 months from enrollment
Clinical definition: reticulocytopenia \< 10x109/L (\< 1%) lasting more than 60 days after HSCT, or Pathological definition: the absence of erythroid precursors in the marrow in the setting of adequate myeloid, lymphoid and megakaryocytic precursors
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| Alberta Children's Hospital | Calgary | Alberta | Recruiting |
More University of Calgary trials in Canada
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT03214354 on ClinicalTrials.gov ↗ ← All trials in Canada